Recent Updates — SPRC
On October 26, 2026, SciSparc Ltd. entered into an inducement offer letter with L.I.A Pure Capital Ltd., agreeing to a reduced exercise price of $1.00 per share for existing warrants. The holder exercised warrants for up to 405,728 ordinary shares, generating approximately $405,728 in aggregate gross proceeds. The transaction is expected to close on or about October 27, 2026, subject to customary conditions. SciSparc intends to use the net proceeds for working capital and general corporate purposes. SciSparc Ltd. operates in the biotechnology sector, focusing on the development of cancer therapies.
Subsidiary NeuroThera Labs completed manufacturing of SCI-110 and obtained European Qualified Person batch release certification, a key regulatory milestone enabling shipment to study sites. This progress supports site activation and the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for Tourette Syndrome across three centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based treatments for central nervous system disorders.
On October 15, 2026, SciSparc Ltd. entered into an inducement offer letter agreement with L.I.A Pure Capital Ltd., the holder of a convertible promissory note issued on February 12, 2026. The company offered to convert the outstanding principal and accrued interest totaling $2,023,039.21 into ordinary shares at a conversion price of $1.50 per share. No additional cash payment is required from the holder, and SciSparc will not receive any cash proceeds from the transaction. The closing is expected to occur on or about October 16, 2026. SciSparc Ltd. operates in the medical technology industry, developing diagnostic devices for infectious diseases.
SciSparc Ltd. announced a strategic shift toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on previous decisions to target the Agentic AI market and establish an advisory board, the company intends to evaluate technologies, companies, and business opportunities across the ecosystem. The firm aims to identify opportunities in these markets but noted there is no assurance that efforts will result in transactions or revenue. SciSparc operates as a clinical-stage pharmaceutical developer focused on cannabinoid-based drug programs.